OUR FACILITIES
WILL REMAIN OPEN & OPERATIONAL DURING THE COVID-19 PANDEMIC

491
Active Clinical Trials
4
Commercial Products
325,000+
Shipments
100+
Countries
Box-for-1OCT2020 

Upcoming Events View All

OCT26

BIO-Europe

Date: October 26-29, 2020

Location: Virtual Event

NOV5

Be The Match: The ONE Forum

Date: November 5-6, 2020

Location: Virtual Event

The Latest From Our Blog View All

Is Your Supply Chain Partner ISO 9001:2015 Certified? Here’s Why Certification Matters

Cell and gene therapies may be considered novel by the general public today, but they are on the path to dramatically improve the lives of those with chronic conditions and cancers. While a handful of therapies have bene commercialized, hundreds of these therapies are currently being administered to patients in clinical trialsand the FDA is likely to approve nearly two dozen more by 2023.  

How the World’s Biggest Biopharma Companies Manage Increasingly Complex Supply Chain Demands

Biopharmaceutical supply chains are among the most complex and costly processes on the planet. CAR T-cell therapies, which can cost hundreds of thousands of dollars to create, can be rendered ineffective with even the slightest temperature deviation during the lengthy apheresis, manufacturing and final product logistics process. The stakes couldn’t be higher: not only is a costly medical therapy on the line, but often, so is a patient’s life. 
 
Recognizing this high risk of failure, biopharmaceutical companies are increasingly customizing aspects of their supply chains. Whether they’re creating unique equipment, packaging, or data reports, they’ve turned to Cryoport’s experts to increase controlunderstanding and efficacy of the development and distribution process.